These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 28172403)

  • 1. Hepatitis C Infection and the Risk of Non-Liver-Related Morbidity and Mortality in HIV-Infected Persons in the Swiss HIV Cohort Study.
    Kovari H; Rauch A; Kouyos R; Rougemont M; Cavassini M; Schmid P; Stöckle M; Bernasconi E; Weber R; Ledergerber B;
    Clin Infect Dis; 2017 Feb; 64(4):490-497. PubMed ID: 28172403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?
    Rockstroh JK; Peters L; Grint D; Soriano V; Reiss P; Monforte Ad; Beniowski M; Losso MH; Kirk O; Kupfer B; Mocroft A;
    J Hepatol; 2013 Aug; 59(2):213-20. PubMed ID: 23583272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study.
    Yeung MW; Young J; Moodie E; Rollet-Kurhajec KC; Schwartzman K; Greenaway C; Cooper C; Cox J; Gill J; Hull M; Walmsley S; Klein MB
    HIV Clin Trials; 2015; 16(3):100-10. PubMed ID: 25972048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
    Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
    J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection.
    Berenguer J; Rodríguez-Castellano E; Carrero A; Von Wichmann MA; Montero M; Galindo MJ; Mallolas J; Crespo M; Téllez MJ; Quereda C; Sanz J; Barros C; Tural C; Santos I; Pulido F; Guardiola JM; Rubio R; Ortega E; Montes ML; Jusdado JJ; Gaspar G; Esteban H; Bellón JM; González-García J;
    Hepatology; 2017 Aug; 66(2):344-356. PubMed ID: 28109003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
    Steininger K; Boyd A; Dupke S; Krznaric I; Carganico A; Munteanu M; Neifer S; Schuetze M; Obermeier M; Arasteh K; Baumgarten A; Ingiliz P
    J Viral Hepat; 2017 Oct; 24(10):832-839. PubMed ID: 28439936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study.
    Ledergerber B; Furrer H; Rickenbach M; Lehmann R; Elzi L; Hirschel B; Cavassini M; Bernasconi E; Schmid P; Egger M; Weber R;
    Clin Infect Dis; 2007 Jul; 45(1):111-9. PubMed ID: 17554711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection.
    Kovari H; Ledergerber B; Battegay M; Rauch A; Hirschel B; Foguena AK; Vernazza P; Bernasconi E; Mueller NJ; Weber R
    Clin Infect Dis; 2010 Feb; 50(4):502-11. PubMed ID: 20085465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.
    Rockstroh JK; Mocroft A; Soriano V; Tural C; Losso MH; Horban A; Kirk O; Phillips A; Ledergerber B; Lundgren J;
    J Infect Dis; 2005 Sep; 192(6):992-1002. PubMed ID: 16107951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.
    Berenguer J; Rodríguez E; Miralles P; Von Wichmann MA; López-Aldeguer J; Mallolas J; Galindo MJ; Van Den Eynde E; Téllez MJ; Quereda C; Jou A; Sanz J; Barros C; Santos I; Pulido F; Guardiola JM; Ortega E; Rubio R; Jusdado JJ; Montes ML; Gaspar G; Esteban H; Bellón JM; González-García J;
    Clin Infect Dis; 2012 Sep; 55(5):728-36. PubMed ID: 22610932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.
    Nahon P; Bourcier V; Layese R; Audureau E; Cagnot C; Marcellin P; Guyader D; Fontaine H; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Leroy V; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Dharancy S; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Benhamou Y; Pilette C; Silvain C; Christidis C; Capron D; Bernard-Chabert B; Zucman D; Di Martino V; Thibaut V; Salmon D; Ziol M; Sutton A; Pol S; Roudot-Thoraval F;
    Gastroenterology; 2017 Jan; 152(1):142-156.e2. PubMed ID: 27641509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term trends in hepatitis C prevalence, treatment uptake and liver-related events in the Swiss HIV Cohort Study.
    Baumann L; Braun DL; Cavassini M; Stoeckle M; Bernasconi E; Schmid P; Calmy A; Haerry D; Béguelin C; Fux CA; Wandeler G; Surial B; Rauch A
    Liver Int; 2024 Jan; 44(1):169-179. PubMed ID: 37850685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response.
    Leone S; Prosperi M; Costarelli S; Nasta P; Maggiolo F; Di Giambenedetto S; Saracino A; Di Pietro M; Gori A
    Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1511-20. PubMed ID: 27272121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study.
    Gjærde LI; Shepherd L; Jablonowska E; Lazzarin A; Rougemont M; Darling K; Battegay M; Braun D; Martel-Laferriere V; Lundgren JD; Rockstroh JK; Gill J; Rauch A; Mocroft A; Klein MB; Peters L
    Clin Infect Dis; 2016 Sep; 63(6):821-829. PubMed ID: 27307505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic.
    Wandeler G; Gsponer T; Bregenzer A; Günthard HF; Clerc O; Calmy A; Stöckle M; Bernasconi E; Furrer H; Rauch A;
    Clin Infect Dis; 2012 Nov; 55(10):1408-16. PubMed ID: 22893583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients.
    Fernández-Montero JV; Vispo E; Barreiro P; Sierra-Enguita R; de Mendoza C; Labarga P; Soriano V
    Clin Infect Dis; 2014 Jun; 58(11):1549-53. PubMed ID: 24633686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe.
    Ingiliz P; Martin TC; Rodger A; Stellbrink HJ; Mauss S; Boesecke C; Mandorfer M; Bottero J; Baumgarten A; Bhagani S; Lacombe K; Nelson M; Rockstroh JK;
    J Hepatol; 2017 Feb; 66(2):282-287. PubMed ID: 27650285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
    Mira JA; Rivero-Juárez A; López-Cortés LF; Girón-González JA; Téllez F; de los Santos-Gil I; Macías J; Merino D; Márquez M; Ríos-Villegas MJ; Gea I; Merchante N; Rivero A; Torres-Cornejo A; Pineda JA;
    Clin Infect Dis; 2013 Jun; 56(11):1646-53. PubMed ID: 23429381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrosis Regression Explains Differences in Outcome in HIV-/HCV-Coinfected Patients with Cirrhosis After Sustained Virological Response.
    Casado JL; Esteban MA; Bañón S; Moreno A; Perez-Elías MJ; Mateos ML; Moreno S; Quereda C
    Dig Dis Sci; 2015 Nov; 60(11):3473-81. PubMed ID: 26112991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.